Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
ナレーター：
-
著者：
What is the difference between MASH and MASLD? In this special episode, Dr. Neil Skolnik breaks down these conditions, which affect insulin resistance of the liver, an area of increasing concern for people with diabetes.
This special episode is sponsored with support from Lilly.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Jay Shubrook, DO, Professor and Diabetologist in the Department of Clinical Sciences and Community Health At Touro University California College of Osteopathic Medicine
Susan Kuchera, MD, Program Director of the Jefferson Health Abington Family MedicineResidency Program and Associate Clinical Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University.
References:
Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease. Gastroenterology, 2026; 171, 164-183
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082
A Clinical Update on MASLD. JAMA Intern Med. 2025;185;(1):105-107. doi:10.1001/jamainternmed.2024.6431